C3 antibody

Catalog No. ABIN1106776

This Mouse Monoclonal antibody specifically detects C3 in IHC (fro), EIA and IHC (p). It exhibits reactivity toward Human.

Quick Overview for C3 antibody (ABIN1106776)

Target: C3 (Complement Component 3 (C3))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This C3 antibody is un-conjugated

Application: Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: BH6

Product Details anti-C3 Antibody

Cross-Reactivity (Details): Species reactivity (tested):Human.

Purification: Protein G Chromatography

Isotype: IgG2a

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.1 mg/mL

Buffer: PBS, 0.02 % Sodium Azide, 0.1 % BSA

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store undiluted at 2-8 °C.

Target Details for C3

Target: C3 (Complement Component 3 (C3))

Alternative Name: Complement C3

Background: The complement system is an important factor in innate immunity. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. Activation products of the complement cascade contain neo-epitopes that are not present in the individual native components. Monoclonal antibodies detecting neo-epitopes have been used for direct quantification of activation at different steps in the complement cascade. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. C3 is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/mL. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections. In ulcerative colitis, and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported. Proteolysis by certain enzymes results in the cleavage of C3 into C3a and C3b. C3b becomes attached to immune complexes and is further cleaved into iC3b, C3c, C3dg and C3f.Synonyms: C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, CPAMD1, Complement component 3

UniProt: P01024

Pathways: Complement System, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Regulation of G-Protein Coupled Receptor Protein Signaling